Ginkgo Bioworks Holdings (DNA) Profit After Tax (2020 - 2026)
Ginkgo Bioworks Holdings' (DNA) quarterly Profit After Tax came in at -$82.6 million in Q1 2026, up 0.87% YoY from -$81.9 million in Q1 2025, and down 135.62% on a QoQ basis from $231.9 million in Q4 2025.
Analysis
Ginkgo Bioworks Holdings (DNA) Profit After Tax (2020 - 2026) Analysis & Trends
Ginkgo Bioworks Holdings (DNA) has 7 years of Profit After Tax data on file, last reported at -$82.6 million in Q1 2026.
- Quarterly Profit After Tax rose 0.87% year-over-year to -$82.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $10.7 million (down 86.65% YoY) and the FY2025 annual result came in at $3.7 million, up 211.16% from the prior year.
- Profit After Tax fell to -$82.6 million in Q1 2026, from $231.9 million in the prior quarter.
- In the past five years, Profit After Tax ranged from a high of $437.4 million in Q4 2024 to a low of -$670.6 million in Q2 2022.
- A 5-year average of -$180.8 million and a median of -$173.0 million in 2023 frame the typical range for Profit After Tax.
- Annual changes were most pronounced in 2022 — Profit After Tax slumped 1143.15% — and 2024, when it jumped 306.63%.
- Tracing DNA's Profit After Tax over 5 years: stood at -$175.5 million in 2022, then slipped by 20.65% to -$211.7 million in 2023, then jumped by 306.63% to $437.4 million in 2024, then plunged by 46.99% to $231.9 million in 2025, then slumped by 135.62% to -$82.6 million in 2026.
- The last three Profit After Tax figures came in at -$82.6 million (Q1 2026), $231.9 million (Q4 2025), and -$80.8 million (Q3 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 140.22 Bn | 132.37 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 86.04 Bn | 78.05 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 63.70 Bn | 58.52 Bn | 1.37 Bn | 472.00 Mn |
| 4 | Moderna | 57.56 Bn | 52.42 Bn | 52.00 Mn | -782.00 Mn |
| 5 | Revolution Medicines | 44.05 Bn | 44.05 Bn | - | -644.37 Mn |
| 6 | BeOne Medicines | 40.16 Bn | 35.06 Bn | 1.53 Bn | 237.01 Mn |
| 7 | Alnylam Pharmaceuticals | 35.63 Bn | 32.32 Bn | 992.69 Mn | 164.49 Mn |
| 8 | Royalty Pharma | 28.63 Bn | 27.79 Bn | - | 81.49 Mn |
| 9 | Insmed | 27.73 Bn | 26.57 Bn | 358.27 Mn | -16.62 Mn |
| 10 | Ginkgo Bioworks Holdings | 430.38 Mn | 345.84 Mn | 18.44 Mn | -57.32 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -57.32 Mn |
| Mar 31, 2026 | -83.24 Mn |
| Dec 31, 2025 | -80.75 Mn |
| Sep 30, 2025 | -80.76 Mn |
| Jun 30, 2025 | -60.30 Mn |
| Mar 31, 2025 | -90.96 Mn |
| Dec 31, 2024 | -109.60 Mn |
| Sep 30, 2024 | -56.40 Mn |
| Jun 30, 2024 | -217.35 Mn |
| Mar 31, 2024 | -168.95 Mn |
| Dec 31, 2023 | -211.43 Mn |
| Sep 30, 2023 | -304.49 Mn |
| Jun 30, 2023 | -173.32 Mn |
| Mar 31, 2023 | -204.97 Mn |
| Dec 31, 2022 | -167.80 Mn |
| Sep 30, 2022 | -672.55 Mn |
| Jun 30, 2022 | -670.57 Mn |
| Mar 31, 2022 | -592.59 Mn |
| Dec 31, 2021 | -1.61 Bn |
| Sep 30, 2021 | -102.41 Mn |